Evidence map›Paper›PMID 39220201›Full record

ArticleIJID regions2024

Prevalence analysis of Chagas disease by age group in an endemic region of Brazil: possible scenario of active vectorial transmission.

Dardiane Santos Cruz, Renata Fiúza Damasceno, Sâmara Fernandes Leite, Mayra Domingues Cardoso, Débora Natália Menezes Almeida, Andreia Brito de Souza, Ana Clara de Jesus Santos, Thallyta Maria Veira, Antônio Luiz Pinho Ribeiro, Léa Campos de Oliveira and 4 more

Abstract read
In one paragraph

Article in IJID regions, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Dardiane Santos CruzPrograma de Pós-graduação em Ciências da Saúde, Universidade Estadual de Montes Claros, Montes Claros, Minas Gerais, Brasil.
Renata Fiúza DamascenoSuperintendência Regional de Saúde de Montes Claros. Secretaria de Estado de Saúde de Minas Gerais, Minas Gerais, Brasil.
Sâmara Fernandes LeitePrograma de Pós-graduação em Ciências da Saúde, Universidade Estadual de Montes Claros, Montes Claros, Minas Gerais, Brasil.
Mayra Domingues CardosoUniversidade Estadual de Montes Claros, Montes Claros, Minas Gerais, Brasil.
Débora Natália Menezes AlmeidaUniversidade Estadual de Montes Claros, Montes Claros, Minas Gerais, Brasil.
Andreia Brito de SouzaPrograma de Pós-graduação em Ciências da Saúde, Universidade Estadual de Montes Claros, Montes Claros, Minas Gerais, Brasil.
Ana Clara de Jesus SantosPrograma de Pós-graduação em Ciências da Saúde, Universidade Estadual de Montes Claros, Montes Claros, Minas Gerais, Brasil.
Thallyta Maria VeiraPrograma de Pós-graduação em Ciências da Saúde, Universidade Estadual de Montes Claros, Montes Claros, Minas Gerais, Brasil.
Antônio Luiz Pinho RibeiroHospital das Clínicas e Faculdade de Medicina da Universidade Federal de Minas Gerais, Belo Horizonte, Brasil.
Léa Campos de OliveiraInstituto de Medicina Tropical, Universidade de São Paulo, São Paulo, Brasil. Faculdade de Medicina.
Ester Cerdeira SabinoInstituto de Medicina Tropical, Universidade de São Paulo, São Paulo, Brasil. Faculdade de Medicina.
Desirée Sant'Ana HaikalPrograma de Pós-graduação em Ciências da Saúde, Universidade Estadual de Montes Claros, Montes Claros, Minas Gerais, Brasil.
Ariela Mota FerreiraPrograma de Pós-graduação em Ciências da Saúde, Universidade Estadual de Montes Claros, Montes Claros, Minas Gerais, Brasil.
Israel MolinaPrograma de Pós-graduação em Ciências da Saúde, Universidade Estadual de Montes Claros, Montes Claros, Minas Gerais, Brasil.

Funding

"Sao Paulo-Minas Gerais Center for Chagas Disease Treatment (SaMiTrop)"U01AI168383 · NIAID · FUNDACAO FACULDADE DE MEDICINA · PI Ester Cerdeira Sabino · 2022 to 2026
$1.9M
NIAID NIH HHS U01 AI168383
6 · The paper itself

Abstract

Objectives: Chagas disease (CD) is an infectious disease that predominantly affects poor and vulnerable populations. The last estimate conducted by the World Health Organization in Latin America regarding the prevalence of CD occurred more than 10 years ago. However, there is a scarcity of data assessing the magnitude of CD in populations residing in considered high-risk regions. Therefore, this study aimed to assess the seroprevalence of CD in an endemic region in Northern Minas Gerais through serologic screening. Methods: This is a prevalence study conducted in the municipalities of Catuti, Mato Verde, Mirabela, Montes Azul, and São Francisco, Minas Gerais, Brazil. Data collection occurred between December 2021 and December 2022, involving a questionnaire with closed-ended questions. The variables analyzed included serologic test results, stratified age groups, health indicators, and housing conditions. Results: Of the 2978 participants, 272 individuals (9.1%) tested positive for CD serology. In the age group of 4 to 14 years, 15 to 49 years, and 50 years or older, the prevalence of positive serology was 0.8% (95% confidence interval [CI] 0.16-1.43), 5.5% (95% CI 4.20-6.83), and 18.8% (95% CI 16.48-21.11), respectively. Among the participating municipalities, Mato Verde had the highest prevalence of positive serology for CD (17%). For participants aged 4 to 14 years with positive serology for CD, first-degree relatives were invited to undergo serologic testing. It was possible to collect samples from relatives of all participants in this age group. However, none of the relatives tested positive. Conclusion: This study identified a 9.1% prevalence of individuals affected by CD who were unaware of their condition. In addition, having infected children in the 4 to 14 age group with mothers with negative serology would rule out congenital transmission of the disease.

Indexed as

BrazilChagas diseasePrevalenceTransmission riskTrypanosoma cruzi

Identifiers

PMID39220201
PMCPMC11364131

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.